Opportunity
Federal Register #FDA2017N5925
FDA Annual Update: Susceptibility Test Interpretive Criteria Standards (Informational Notice)
Buyer
Food and Drug Administration
Posted
May 12, 2026
Identifier
FDA2017N5925
This notice from the Food and Drug Administration (FDA) provides an annual update on the Susceptibility Test Interpretive Criteria (STIC) web page, as required by the 21st Century Cures Act. - Government Buyer: - Department of Health and Human Services - Food and Drug Administration (FDA) - Center for Drug Evaluation and Research - OEMs and Vendors: - Clinical and Laboratory Standards Institute (CLSI) is referenced as the standards-setting organization - Products/Services Requested: - No procurement of products or services is being solicited - Notice covers updates to recognized susceptibility test interpretive criteria standards for various antibacterial and antifungal agents - Drugs mentioned include Amikacin, Amoxicillin and Clavulanate, Azithromycin, Cefepime, Clindamycin, Colistimethate, Gentamicin, Isavuconazonium sulfate, Piperacillin, Polymyxin B Sulfate, Rifampin, Tobramycin, Voriconazole, Zoliflodacin, and others - Unique or Notable Requirements: - The notice is informational only and invites public comment on the updates - Details the process for recognition or withdrawal of recognition for susceptibility test standards - No contract, purchase, or award is associated with this notice
Description
The Food and Drug Administration (FDA) announces the availability of its annual compilation of notices of updates to the Susceptibility Test Interpretive Criteria web page, established on December 13, 2017. This compilation includes updates to the format of the web pages and the susceptibility test interpretive criteria recognized by FDA. The notice is published in accordance with the 21st Century Cures Act and provides for public comment on the updates. The FDA recognizes or withdraws recognition of susceptibility test interpretive criteria standards and makes necessary updates to the lists published on the web page. Comments can be submitted electronically or in writing as detailed in the notice.